Eagle Pharmaceuticals (NASDAQ:EGRX) Receives New Coverage from Analysts at StockNews.com

Investment analysts at StockNews.com assumed coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a research report issued on Sunday. The brokerage set a “hold” rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Stock Up 11.6 %

EGRX stock opened at $5.60 on Friday. Eagle Pharmaceuticals has a 52 week low of $3.21 and a 52 week high of $23.52. The company has a fifty day simple moving average of $4.20 and a two-hundred day simple moving average of $4.92. The firm has a market capitalization of $72.74 million, a P/E ratio of 4.75 and a beta of 0.45.

Hedge Funds Weigh In On Eagle Pharmaceuticals

Several institutional investors have recently bought and sold shares of EGRX. Trexquant Investment LP lifted its position in Eagle Pharmaceuticals by 26.1% during the third quarter. Trexquant Investment LP now owns 67,187 shares of the specialty pharmaceutical company’s stock valued at $1,060,000 after purchasing an additional 13,910 shares during the last quarter. Adage Capital Partners GP L.L.C. lifted its position in Eagle Pharmaceuticals by 25.0% during the third quarter. Adage Capital Partners GP L.L.C. now owns 500,000 shares of the specialty pharmaceutical company’s stock valued at $7,885,000 after purchasing an additional 100,000 shares during the last quarter. Kennedy Capital Management LLC bought a new position in Eagle Pharmaceuticals during the third quarter valued at $575,000. Connors Investor Services Inc. lifted its holdings in shares of Eagle Pharmaceuticals by 24.8% in the 3rd quarter. Connors Investor Services Inc. now owns 12,566 shares of the specialty pharmaceutical company’s stock worth $198,000 after acquiring an additional 2,500 shares during the last quarter. Finally, DGS Capital Management LLC bought a new stake in shares of Eagle Pharmaceuticals in the 4th quarter worth about $60,000. Institutional investors own 85.36% of the company’s stock.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma.